Document is current
Any future updates will be listed below
-
Authors
Gurney, Mark https://orcid.org/0000-0002-7062-2644
Mangaonkar, Abhishek A. https://orcid.org/0000-0003-2458-9887
Lasho, Terra
Finke, Christy
Al-Kali, Aref https://orcid.org/0000-0002-0824-3715
Gangat, Naseema
Shah, Mithun V. https://orcid.org/0000-0002-5359-336X
Alkhateeb, Hassan B.
Tefferi, Ayalew https://orcid.org/0000-0003-4605-3821
Sallman, David https://orcid.org/0000-0003-0504-8233
Xie, Zhuoer https://orcid.org/0000-0003-1266-9804
Viswanatha, David
Reichard, Kaaren
Al Ali, Najla
Komrokji, Rami https://orcid.org/0000-0002-1876-5269
Padron, Eric https://orcid.org/0000-0002-4707-7916
Patnaik, Mrinal M. https://orcid.org/0000-0001-6998-662X
- License Information
-
More Information
Article History
Received: 2 March 2023
Revised: 15 June 2023
Accepted: 29 June 2023
First Online: 8 July 2023
Competing interests
: MMP has received research funding from Kura Oncology, StemLine Pharmaceuticals and Epigenetix. He has served on the advisory board for CTI Pharmaceuticals.
